A method for treating chronic myeloid leukemia in a subject, comprising administering to said subject a compound inhibiting the mutation of T315I in a BCR-ABL tyrosine kinase, wherein said compound is N-methyl-2- [3- ((E) -2-pyridin-2 -yl-vinyl) -1H-indazol-6-ylsulfanyl] -benzamide, or a pharmaceutically acceptable salt thereof. The method of claim 1, wherein the subject is a human. A method for treating chronic myeloid leukemia in a subject having a T315I mutation in BCR-ABL tyrosine kinase comprising administering to said subject a compound comprising N-methyl-2- [3 - ((E) -2-pyridin-2-yl-vinyl) -1H-indazol-6-ylsulfanyl] -benzamide, or a pharmaceutically acceptable salt thereof. The method of claim 3, wherein the subject is a human. A method for treating chronic myeloid leukemia in a subject having a T315I mutation in BCR-ABL tyrosine kinase, comprising administering to said subject a compound inhibiting the T315I mutation in BCR-ABL tyrosine kinase, wherein said compound is N-methyl-2- [3 - ((E) -2-pyridin-2-yl-vinyl) -1H-indazol- 6-ylsulfanyl] -benzamide or a pharmaceutically acceptable salt thereof. The method of claim 5, wherein the subject is a human. A pharmaceutical composition for the treatment of chronic myeloid leukemia in a subject comprising a compound inhibiting the mutation of T315I in a BCR-ABL tyrosine kinase, wherein said compound is N-methyl-2- [3- ((E) -2-pyridin-2-yl- vinyl) -1H-indazol-6-ylsulfanyl] -benzamide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. wherein said compound is N-methyl-2- [3 - ((E) -2-pyridin-2-yl-vinyl) -1H-indazol-6-ylsulfanyl] -benzamide or a pharmaceutically acceptable salt thereof. The method of claim 5, wherein the subject is a human. A pharmaceutical composition for the treatment of chronic myeloid leukemia in a subject comprising a compound inhibiting the mutation of T315I in a BCR-ABL tyrosine kinase, wherein said compound is N-methyl-2- [3- ((E) -2-pyridin-2-
